hematologic cancer News
-
IMV Inc. to Present at Two Investor Conferences in September
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be presenting at two investor conferences in September. Please find ...
By IMV Inc.
-
IMV Inc. to Present at the H.C. Wainwright Global Investment Conference
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be participating in person at the H.C. Wainwright Global Investment ...
By IMV Inc.
-
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today announced that on July 7, 2022, IMV Inc. (the “Company”) received a letter ...
By IMV Inc.
-
IMV Re-Establishes Its At-the-Market Facility Under Renewed Base Shelf Prospectus
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it plans to maintain its existing at-the-market facility initially ...
By IMV Inc.
-
IMV Inc. Announces Strategic Reorganization
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today announced a strategic reorganization together with the appointment of ...
By IMV Inc.
-
IMV Strengthens Its Financial Position With the $US10 Million Drawdown From Its Existing Long-Term Debt Facility
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the drawdown of the remaining US$10 million available under its existing US$25 million debt facility led by Horizon Technology ...
By IMV Inc.
-
IMV Provides an Update on The VITALIZE Trial
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today provided an update on the open-label VITALIZE study evaluating its lead product maveropepimut-S (MVP-S) in combination ...
By IMV Inc.
-
Thermo Fisher Scientific and JW Therapeutics Announce CAR-T Partnership in China
Thermo Fisher Scientific, the world leader in serving science, has signed an agreement with JW Therapeutics, a leading cell therapy company, to ensure non-exclusive commercial access to Thermo Fisher's Gibco CTS Dynabeads CD3/CD28. The agreement will support the clinical development and commercial manufacturing of leading CAR-T (Chimeric Antigen Receptor T-Cells) therapies in China, including JW ...
-
Abologix wins CHF 150,000 to develop targeted antibodies for cancer patients
Abologix develops a new therapeutic option to treat lymphoma patients who have become resistant to conventional treatments. The Geneva-based biotech startup is a spin-out from the laboratories at the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG). Abologix will use the CHF 150,000 to advance the preclinical development of its product, refine its commercial and competitive ...
By Abologix
-
Agilent Technologies Introduces Two Innovative Products to Advance Clinical Cancer Research
Agilent Technologies Inc. (NYSE: A) today launched two new products-the HaloPlexHS target enrichment system and ClearSeq Comprehensive Cancer research panel-designed to improve the speed and accuracy of clinical cancer research. Both products will enable researchers to rapidly and accurately identify disease-associated variants in tumor samples-information that can be vital to research in cancer ...
-
Agilent Introduces CGH+SNP cancer microarrays and Cytogenomics software for cancer research
Agilent Technologies Inc., (NYSE: A) today introduced SurePrint G3 CGH+SNP cancer catalog microarrays, addressing the growing need of researchers to detect both copy number and copy-neutral aberrations in cancer tissue samples in the same experiment. The new microarray release is accompanied by the release of Agilent CytoGenomics 2.0 software, which now includes support for CGH+SNP analysis of ...
-
ABOLOGIX founded in Geneva, Switzerland
Abologix was launched today, and it is the newest addition to the biotechnology ecosystem in the city of Geneva (Switzerland). The three founders of Abologix are Dr.Ignacio Faus, Prof. Beat Imhof and Prof. Thomas Matthes.The company intends to develop novel monoclonal antibodies for the treatment of JAM-C positive hematological tumours.New therapeutics for the treatment of difficult to manage ...
By Abologix
-
Jubilant Therapeutics Inc. Doses First Patient in Phase I/II Trial Evaluating JBI-802, dual inhibitor of LSD1 and HDAC6, in patients with advanced solid tumors
JBI-802 is a first-in-class, orally administered, dual equipotent inhibitor of LSD1 & HDAC6 JBI-802 demonstrated synergistic anti-tumor activity in animal models Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced the dosing of the first patient in a ...
-
Protecting the Immunocompromised from Invasive Mold Infection Risks in Hospitals and Buildings throughout Puerto Rico
Anyone with a weakened or suppressed immune system could be at heightened risk of developing an invasive mold infection. The Centers for Disease Control and Prevention (CDC) warns that these types of infections can occur days to weeks after exposure to fungi that live in the environment. The agency goes so far as to advise physicians to keep invasive mold infections in mind when treating people ...
-
Arch Oncology Receives U.S. FDA Orphan Drug Designation for AO-176, a Next-Generation Anti-CD47 IgG2 Antibody, for the Treatment of Multiple Myeloma
BRISBANE, CA and ST. LOUIS, MO, January 21, 2022 – Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to AO-176 on January 3rd, 2022, for the treatment of relapsed/refractory multiple myeloma (r/r MM). AO-176, ...
-
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDU (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. ORSERDU is the first endocrine innovation in more than 20 years, specifically addressing ESR1 mutations, a major unmet need. The Menarini Group (“Menarini”), a ...
-
Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting
BURLINGTON, Mass. and OXFORD, UK, October 19, 2021 - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced presentations on Axumin® (fluciclovine F 18) and 18F-fluciclovine at the upcoming American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting, to be held in Chicago, III., ...
-
T-knife Completes € 66 Million Series A Financing to Develop Next-Generation T-Cell Therapies
T-knife’s proprietary humanized mouse platform (HuTCR) T-cell receptors expected to provide superior affinity/specificity properties - Series A round led by Versant Ventures and RA Capital Management, with strong participation from seed investors Andera Partners and BIVF BERLIN, Germany, August 06, 2020/GlobeNewswire/– T-knife GmbH, a next-generation adoptive T-cell ...
By T-Knife GmbH
-
Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
Dr. Daugherty has 40+ years of experience managing biotechnology projects and companies focused on cancer, immunology, vaccines, and nutraceuticals Dr. Daugherty will serve as medical monitor for the upcoming Phase III clinical trial and for potential future clinical trials, focusing on assessing any safety issues that arise on a real-time basis, leveraging his MD from the University of ...
-
Immune-Onc Therapeutics Doses First Patient in Phase 1 Clinical Trial of IO-202, a First-in-Class Myeloid Checkpoint Inhibitor Targeting LILRB4, in Patients with Advanced Solid Tumors
Phase 1 multicenter dose-escalation and dose-expansion trial evaluating IO-202 as a monotherapy and in combination with an anti-PD-1 is initiated and expected to enroll 200 patientswith advanced solid tumors This is the second clinical trial for the IO-202 program; its first Phase 1 trial is currently enrolling patients with acute myeloid leukemia (AML) or chronic myelomonocytic leukemia ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you